Signet Therapeutics Named to '2024 Top 50 Hard-Tech Changemakers' by CB Insights China

On December 20th, the Future Unicorn Conference and Annual Meeting of Entrepreneurship organized by VentureBeat concluded successfully in Chengdu. SIGNET, as the first innovative targeted drug research and development company in China based on organoid disease models + AI, was selected for its groundbreaking research progress.Top 50 Hard Tech Innovators to Watch in 2024」。

Based on the significant importance of technological innovation in the early stages for leading scientific and technological development and promoting progress in the times, CYZONE collaborates with Zhongguancun Zhiyou Research Institute to launch the "Hard Tech Changemakers List" selection activity in China.Aimed at discovering outstanding hard tech entrepreneurs, contributing to the continuous prosperity and development of China's hard technology ecosystem.

After six months of rigorous selection, which saw enthusiastic participation from companies and strong recommendations from investment institutions, the evaluation event attracted over a hundred enterprises to successfully submit applications. The selection process followed an evaluation mechanism that combined internal preliminary reviews with scores and comments from external expert judges, taking into account the enterprises'Technological and Product Achievements, Commercial Value and Potential, and Founding Team InfluenceThe comprehensive performance in the three major review dimensions ultimately unveiled the "Top 50 Hard Tech Innovators to Watch in 2024" list.

Signet Therapeutics is the first biotech company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. Initially founded on the Harvard University campus, it was established in Shenzhen by the end of 2020, securing nearly 220 million yuan in financing and project funding. The company currently has four drug pipelines, with the lead pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has successively received IND approval from the U.S. FDA and China NMPA, as well as Orphan Drug Designation from the U.S. FDA, and has now entered Phase I clinical trials.

Signet is not only the phonetic translation of Signet but also adheres to the vision of "Full of Hope, Studying Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and new target discovery. Combined with AI-powered screening, synthesis, and optimization of small molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has a 1200㎡ R&D facility and a 500㎡ experimental animal housing area. SIGNET's organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative enterprises include Shenzhen BrightGene Bio-Medical Technology and Genuine Biotech, helping to bring more innovative drugs to life.